Developer docs
API playgroundTry for free, no card

Search company profiles

CorriXR Therapeutics

Full company profile

uuid0000ns2

Namestring
CorriXR Therapeutics
Legal namestring
CorriXR Therapeutics, Inc.
Websiteurl
corrixr.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

CorriXR Therapeutics is a privately held, preclinical biotechnology company developing CRISPR/Cas-based gene editing therapies for solid tumor oncology, with a primary focus on lung, head & neck, and esophageal squamous cell carcinomas. The company's lead asset, CXR101, uses a proprietary CRISPR-based approach to disable NRF2 — a transcription factor chronically hyperactive in squamous tumors that drives survival, treatment resistance, immune evasion, and metabolic reprogramming — by delivering the editing machinery directly to the tumor site via ionizable lipid nanoparticles (LNPs). This localized delivery architecture is designed to concentrate therapeutic activity in the tumor while limiting systemic exposure relative to conventional chemotherapy and radiation. Preclinical studies published in 2025 demonstrated that editing 20-40% of lung squamous cell carcinoma cells resensitized tumors to chemotherapy with minimal off-target effects, and the company has received positive FDA feedback ahead of a planned first-in-human trial. CorriXR also has a collaboration with InhaTarget Therapeutics (Belgium) and Merxin Ltd (UK) to develop an inhaled CRISPR gene-editing therapy for squamous cell lung carcinoma, extending the platform beyond intratumoral LNP administration.

The company was founded in 2022 as a spinout of the ChristianaCare Gene Editing Institute, where founder and Chief Scientific Officer Eric B. Kmiec, Ph.D. leads the underlying research program alongside 35+ years of gene editing experience, 165 peer-reviewed publications, and 15 issued patents. CorriXR is headquartered in Newark, Delaware, employs 11-50 people, and is led by CEO Hilary M. Malone, Ph.D. (formerly Chief Regulatory Officer at Sanofi and COO at Valo Health) and COO Jan Case (formerly of Spark Therapeutics, where she supported the Luxturna FDA approval). Capital sources to date include a 2022 founding round of approximately $6.5M from ChristianaCare Health Systems and Brookhaven Bio, two $1M grants from the State of Delaware (2023 and 2025), a January 2024 seed investment from Cortado Ventures, and an exempt securities offering of more than $8M in early 2024.

CorriXR is pre-revenue and pre-commercial; all current activity is directed at advancing CXR101 through IND-enabling studies, regulatory submissions, and first-in-human clinical execution. The company has no approved product, no disclosed pricing, and no active distribution channels. Future revenue mechanics are described as licensing/royalties, contingent on successful clinical development and regulatory approval. As such, the business is currently financed entirely through private capital and state grants, with the go-to-market motion channeled through scientific publication, conference presentation, clinical advisor networks, and institutional partnerships rather than conventional demand generation.

Short descriptiontext

CorriXR Therapeutics is a preclinical, privately held biotechnology company developing CRISPR/Cas gene editing therapies — led by candidate CXR101 — that disable NRF2 in lung, head & neck, and esophageal squamous cell carcinomas, delivered via lipid nanoparticles to overcome chemotherapy resistance.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNewark, United States
HQ citystring
Newark
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CRISPR gene therapy, oncology therapeutics, squamous cell carcinoma, gene editing platform, targeted genetic medicine
Industry1 code
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-commercial / Pipeline Development
TypeLicensing Royalties
Description

CorriXR is a pre-revenue biotherapeutics company. All current activity is focused on advancing CXR101 through preclinical development, IND submission, and into first-in-human clinical trials. Revenue generation is contingent on successful clinical development and regulatory approval.

corrixr.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CorriXR Therapeutics is developing CXR101, a targeted CRISPR/Cas-based genetic medicine that disables the NRF2 transcription factor in squamous cell carcinomas of the lung, head & neck, and esophagus. The therapy uses ionizable lipid nanoparticles (LNPs) to deliver the gene-editing payload directly to the tumor site, aiming to restore chemosensitivity and limit systemic toxicity. The company is pre-commercial and advancing the program through preclinical studies toward first-in-human clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Editing 20-40% of lung squamous cell carcinoma cells resensitized tumors to chemotherapy with minimal off-target effects in preclinical studies
Product overview1 text field

CorriXR Therapeutics is developing targeted genetic medicine therapies for oncology. The company's lead product is CXR101, a CRISPR-based gene editing therapy targeting NRF2 for the treatment of squamous cell cancers. The company is also developing an inhaled CRISPR gene-editing therapy in collaboration with InhaTarget Therapeutics and Merxin Ltd for squamous cell lung carcinoma.

Product and service1 record
1CXR101
CategoryOncology Gene Therapy
Description

CXR101 is CorriXR's lead therapeutic candidate — a CRISPR/Cas-based gene editing therapy designed to disable the NRF2 transcription factor in lung, head & neck, and esophageal squamous cell carcinomas. It is delivered directly to the tumor site via ionizable lipid nanoparticles (LNPs), with the goal of restoring chemosensitivity and limiting systemic toxicity in patients with treatment-resistant solid tumors.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Belgium-based InhaTarget Therapeutics is collaborating with CorriXR on the development of an inhaled CRISPR gene-editing therapy for squamous cell lung carcinoma. The collaboration represents a core strategic partnership focused on inhalation delivery of the company's gene editing platform.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

UK-based Merxin Ltd is collaborating with CorriXR on the development of an inhaled CRISPR gene-editing therapy for squamous cell lung carcinoma, working alongside InhaTarget Therapeutics. The partnership extends the company's delivery platform capabilities for inhaled genetic medicine.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CorriXR emerged directly from pioneering gene editing research at the ChristianaCare Gene Editing Institute (GEI), one of the nation's leading centers for translational genetic medicine. GEI serves as the company's primary R&D engine, providing PDX and PDC mouse model validation, in vitro and in vivo studies, cell model development, and next-generation sequencing capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage company developing prime editing, a search-and-replace gene editing technology, for genetic diseases and oncology. Comparable to CorriXR as a next-generation gene editing platform pursuing therapeutics in oncology, though at an earlier stage of clinical translation.

TypeDirect peer
Description

Clinical-stage gene editing company using CRISPR/Cas9 and CRISPR/Cas12a for both in vivo and ex vivo therapies targeting rare genetic diseases and oncology. Directly comparable to CorriXR in CRISPR platform and therapeutic ambition, with multiple clinical-stage assets.

TypeEmerging player
Description

Clinical-stage company developing in vivo gene editing therapies using base editing and LNP delivery for cardiovascular disease. Highly comparable to CorriXR on in vivo gene editing modality and LNP delivery, though focused on cardiovascular indications rather than oncology.

TypeDirect peer
Description

Clinical-stage CRISPR genome editing company developing allogeneic CAR-T cell therapies for hematologic malignancies. Directly comparable to CorriXR in CRISPR platform technology, with oncology focus, though differentiated by ex vivo cell therapy versus in vivo gene editing.

TypeBroad incumbent
Description

Clinical-stage genomic medicine company using zinc finger nucleases (ZFNs) for in vivo and ex vivo gene editing therapies across multiple indications. Comparable as a broad gene editing platform company with clinical-stage assets, though using a non-CRISPR nuclease platform.

TypeDirect peer
Description

Clinical-stage CRISPR/Cas9-based gene editing company developing in vivo and ex vivo gene-editing therapies for hemoglobinopathies, oncology, and regenerative medicine. Most directly comparable to CorriXR as both use CRISPR/Cas platforms to develop in vivo gene-editing therapeutics, with overlapping delivery technologies (LNPs).

TypeEmerging player
Description

Preclinical-stage company developing 'gene writing' technology — a novel platform for writing therapeutic messages into the genome. Comparable to CorriXR as a next-generation gene medicine platform pursuing in vivo therapies, though with a different underlying writing modality than CRISPR knockout.

TypeDirect peer
Description

Clinical-stage company developing in vivo CRISPR/Cas9-based gene editing therapies using LNP delivery for genetic diseases and oncology. Highly comparable to CorriXR on platform technology (CRISPR/Cas) and delivery modality (LNPs), and a direct competitor for gene editing talent and partnerships.

9Excision BioTherapeutics
TypeDirect peer
Description

Clinical-stage CRISPR-based gene therapy company developing therapies for infectious diseases. Directly comparable to CorriXR on CRISPR gene therapy platform; notable that CorriXR's CMC leader Panos Argiras was previously Senior Director of CMC Manufacturing for CRISPR-based Gene Therapy at Excision, indicating talent flow overlap.

TypeDirect peer
Description

Clinical-stage precision genetic medicines company using base editing — a CRISPR-derived technology — for genetic diseases and oncology. Closely comparable to CorriXR as a next-generation gene editing platform developing precision therapeutics, including programs with LNP delivery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CorriXR Therapeutics

Oncology Therapeuticscorrixr.com

CorriXR Therapeutics is a preclinical, privately held biotechnology company developing CRISPR/Cas gene editing therapies — led by candidate CXR101 — that disable NRF2 in lung, head & neck, and esophageal squamous cell carcinomas, delivered via lipid nanoparticles to overcome chemotherapy resistance.

What CorriXR Therapeutics does

CorriXR Therapeutics is a privately held, preclinical biotechnology company developing CRISPR/Cas-based gene editing therapies for solid tumor oncology, with a primary focus on lung, head & neck, and esophageal squamous cell carcinomas. The company's lead asset, CXR101, uses a proprietary CRISPR-based approach to disable NRF2 — a transcription factor chronically hyperactive in squamous tumors that drives survival, treatment resistance, immune evasion, and metabolic reprogramming — by delivering the editing machinery directly to the tumor site via ionizable lipid nanoparticles (LNPs). This localized delivery architecture is designed to concentrate therapeutic activity in the tumor while limiting systemic exposure relative to conventional chemotherapy and radiation. Preclinical studies published in 2025 demonstrated that editing 20-40% of lung squamous cell carcinoma cells resensitized tumors to chemotherapy with minimal off-target effects, and the company has received positive FDA feedback ahead of a planned first-in-human trial. CorriXR also has a collaboration with InhaTarget Therapeutics (Belgium) and Merxin Ltd (UK) to develop an inhaled CRISPR gene-editing therapy for squamous cell lung carcinoma, extending the platform beyond intratumoral LNP administration.

The company was founded in 2022 as a spinout of the ChristianaCare Gene Editing Institute, where founder and Chief Scientific Officer Eric B. Kmiec, Ph.D. leads the underlying research program alongside 35+ years of gene editing experience, 165 peer-reviewed publications, and 15 issued patents. CorriXR is headquartered in Newark, Delaware, employs 11-50 people, and is led by CEO Hilary M. Malone, Ph.D. (formerly Chief Regulatory Officer at Sanofi and COO at Valo Health) and COO Jan Case (formerly of Spark Therapeutics, where she supported the Luxturna FDA approval). Capital sources to date include a 2022 founding round of approximately $6.5M from ChristianaCare Health Systems and Brookhaven Bio, two $1M grants from the State of Delaware (2023 and 2025), a January 2024 seed investment from Cortado Ventures, and an exempt securities offering of more than $8M in early 2024.

CorriXR is pre-revenue and pre-commercial; all current activity is directed at advancing CXR101 through IND-enabling studies, regulatory submissions, and first-in-human clinical execution. The company has no approved product, no disclosed pricing, and no active distribution channels. Future revenue mechanics are described as licensing/royalties, contingent on successful clinical development and regulatory approval. As such, the business is currently financed entirely through private capital and state grants, with the go-to-market motion channeled through scientific publication, conference presentation, clinical advisor networks, and institutional partnerships rather than conventional demand generation.

CorriXR Therapeutics firmographics

Firmographics
Name
CorriXR Therapeutics
Legal name
CorriXR Therapeutics, Inc.
Website
https://corrixr.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
CorriXR Therapeutics is a preclinical, privately held biotechnology company developing CRISPR/Cas gene editing therapies — led by candidate CXR101 — that disable NRF2 in lung, head & neck, and esophageal squamous cell carcinomas, delivered via lipid nanoparticles to overcome chemotherapy resistance.
Ownership category
akta.pro rank

CorriXR Therapeutics industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Keywords

  • CRISPR gene therapy
  • Oncology therapeutics
  • Squamous cell carcinoma
  • Gene editing platform
  • Targeted genetic medicine

Where CorriXR Therapeutics is headquartered

Location

Headquarters

HQ city
Newark
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CorriXR Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pre-commercial / Pipeline Development: CorriXR is a pre-revenue biotherapeutics company. All current activity is focused on advancing CXR101 through preclinical development, IND submission, and into first-in-human clinical trials. Revenue generation is contingent on successful clinical development and regulatory approval.

Go-to-market motion1 record

Marketing channels4 records

CorriXR Therapeutics product offering

Product offering

Core offering

CorriXR Therapeutics is developing CXR101, a targeted CRISPR/Cas-based genetic medicine that disables the NRF2 transcription factor in squamous cell carcinomas of the lung, head & neck, and esophagus. The therapy uses ionizable lipid nanoparticles (LNPs) to deliver the gene-editing payload directly to the tumor site, aiming to restore chemosensitivity and limit systemic toxicity. The company is pre-commercial and advancing the program through preclinical studies toward first-in-human clinical trials.

Product overview

CorriXR Therapeutics is developing targeted genetic medicine therapies for oncology. The company's lead product is CXR101, a CRISPR-based gene editing therapy targeting NRF2 for the treatment of squamous cell cancers. The company is also developing an inhaled CRISPR gene-editing therapy in collaboration with InhaTarget Therapeutics and Merxin Ltd for squamous cell lung carcinoma.

Differentiator

Problem solved

Functional benefit

Products and services

  • CXR101 CXR101 is CorriXR's lead therapeutic candidate — a CRISPR/Cas-based gene editing therapy designed to disable the NRF2 transcription factor in lung, head & neck, and esophageal squamous cell carcinomas. It is delivered directly to the tumor site via ionizable lipid nanoparticles (LNPs), with the goal of restoring chemosensitivity and limiting systemic toxicity in patients with treatment-resistant solid tumors.

Quantifiable outcome

  • Editing 20-40% of lung squamous cell carcinoma cells resensitized tumors to chemotherapy with minimal off-target effects in preclinical studies

Companies that use CorriXR Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

CorriXR Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CorriXR Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • InhaTarget TherapeuticsflagshipStrategic or Co-development Partner · 1 January 2025Belgium-based InhaTarget Therapeutics is collaborating with CorriXR on the development of an inhaled CRISPR gene-editing therapy for squamous cell lung carcinoma. The collaboration represents a core strategic partnership focused on inhalation delivery of the company's gene editing platform.
  • Merxin LtdflagshipStrategic or Co-development Partner · 1 January 2025UK-based Merxin Ltd is collaborating with CorriXR on the development of an inhaled CRISPR gene-editing therapy for squamous cell lung carcinoma, working alongside InhaTarget Therapeutics. The partnership extends the company's delivery platform capabilities for inhaled genetic medicine.
  • ChristianaCare Gene Editing InstitutecoreStrategic or Co-development PartnerCorriXR emerged directly from pioneering gene editing research at the ChristianaCare Gene Editing Institute (GEI), one of the nation's leading centers for translational genetic medicine. GEI serves as the company's primary R&D engine, providing PDX and PDC mouse model validation, in vitro and in vivo studies, cell model development, and next-generation sequencing capabilities.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

CorriXR Therapeutics competitors and assessment

Company assessment

Emerging players

  • Prime Medicine: Clinical-stage company developing prime editing, a search-and-replace gene editing technology, for genetic diseases and oncology. Comparable to CorriXR as a next-generation gene editing platform pursuing therapeutics in oncology, though at an earlier stage of clinical translation.
  • Verve Therapeutics: Clinical-stage company developing in vivo gene editing therapies using base editing and LNP delivery for cardiovascular disease. Highly comparable to CorriXR on in vivo gene editing modality and LNP delivery, though focused on cardiovascular indications rather than oncology.
  • Tessera Therapeutics: Preclinical-stage company developing 'gene writing' technology — a novel platform for writing therapeutic messages into the genome. Comparable to CorriXR as a next-generation gene medicine platform pursuing in vivo therapies, though with a different underlying writing modality than CRISPR knockout.

Direct peers

  • Editas Medicine: Clinical-stage gene editing company using CRISPR/Cas9 and CRISPR/Cas12a for both in vivo and ex vivo therapies targeting rare genetic diseases and oncology. Directly comparable to CorriXR in CRISPR platform and therapeutic ambition, with multiple clinical-stage assets.
  • Caribou Biosciences: Clinical-stage CRISPR genome editing company developing allogeneic CAR-T cell therapies for hematologic malignancies. Directly comparable to CorriXR in CRISPR platform technology, with oncology focus, though differentiated by ex vivo cell therapy versus in vivo gene editing.
  • CRISPR Therapeutics: Clinical-stage CRISPR/Cas9-based gene editing company developing in vivo and ex vivo gene-editing therapies for hemoglobinopathies, oncology, and regenerative medicine. Most directly comparable to CorriXR as both use CRISPR/Cas platforms to develop in vivo gene-editing therapeutics, with overlapping delivery technologies (LNPs).
  • Intellia Therapeutics: Clinical-stage company developing in vivo CRISPR/Cas9-based gene editing therapies using LNP delivery for genetic diseases and oncology. Highly comparable to CorriXR on platform technology (CRISPR/Cas) and delivery modality (LNPs), and a direct competitor for gene editing talent and partnerships.
  • Excision BioTherapeutics: Clinical-stage CRISPR-based gene therapy company developing therapies for infectious diseases. Directly comparable to CorriXR on CRISPR gene therapy platform; notable that CorriXR's CMC leader Panos Argiras was previously Senior Director of CMC Manufacturing for CRISPR-based Gene Therapy at Excision, indicating talent flow overlap.
  • Beam Therapeutics: Clinical-stage precision genetic medicines company using base editing — a CRISPR-derived technology — for genetic diseases and oncology. Closely comparable to CorriXR as a next-generation gene editing platform developing precision therapeutics, including programs with LNP delivery.

Broad incumbents

  • Sangamo Therapeutics: Clinical-stage genomic medicine company using zinc finger nucleases (ZFNs) for in vivo and ex vivo gene editing therapies across multiple indications. Comparable as a broad gene editing platform company with clinical-stage assets, though using a non-CRISPR nuclease platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

CorriXR Therapeutics social profiles

Digital presence

CorriXR Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CorriXR Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

CorriXR Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CorriXR Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CorriXR Therapeutics

What does CorriXR Therapeutics do?

CorriXR Therapeutics is developing CXR101, a targeted CRISPR/Cas-based genetic medicine that disables the NRF2 transcription factor in squamous cell carcinomas of the lung, head & neck, and esophagus. The therapy uses ionizable lipid nanoparticles (LNPs) to deliver the gene-editing payload directly to the tumor site, aiming to restore chemosensitivity and limit systemic toxicity. The company is pre-commercial and advancing the program through preclinical studies toward first-in-human clinical trials.

Is CorriXR Therapeutics a public or private company?

CorriXR Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was CorriXR Therapeutics founded?

CorriXR Therapeutics was founded in 2022. It employs 1 to 10 people.

Where is CorriXR Therapeutics based?

CorriXR Therapeutics is headquartered in Newark, United States, in the North America region.

How does CorriXR Therapeutics make money?

One revenue line is on record: pre-commercial / Pipeline Development.

Who are CorriXR Therapeutics's main competitors?

Emerging players on record are Prime Medicine, Verve Therapeutics and Tessera Therapeutics. Direct peers are Editas Medicine, Caribou Biosciences, CRISPR Therapeutics, Intellia Therapeutics, Excision BioTherapeutics and Beam Therapeutics. Sangamo Therapeutics is listed as a broad incumbent.

Does CorriXR Therapeutics have an API?

No public API is recorded for CorriXR Therapeutics.

What industry is CorriXR Therapeutics in?

CorriXR Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceCorrixr Therapeutics Names Nancy Whiting, PharmD, as Board ChairCorrixr Therapeutics appointed Nancy Whiting, PharmD, as board chair, succeeding Janice Nevin, who will retire from ChristianaCare in September 2026. Whiting brings 15 years at Seagen and 5 years at Recludix Pharma. The appointment comes as Corrixr advances CXR101 toward IND filing and first-in-human trials.citybizCorrixr Therapeutics Appoints Nancy Whiting as Board Chair Ahead of Clinical MilestoneCorrixr Therapeutics has appointed Nancy Whiting, an oncology drug development executive with over two decades of biotechnology experience, as chair of its board of directors, succeeding Janice E. Nevin who is retiring as president and CEO of ChristianaCare. The leadership transition comes as Corrixr advances its lead genetic medicine candidate CXR101 toward an investigational new drug filing and first-in-human proof-of-mechanism studies targeting squamous cell carcinomas of the lung, head, neck, and esophagus. Whiting previously served as CEO of Recludix Pharma and held executive leadership positions at Seagen, where she contributed to multiple oncology therapy approvals.Via TTCorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer TreatmentCorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd have entered a strategic collaboration to develop an inhaled genetic therapy targeting squamous cell lung carcinoma using CorriXR's CRISPR-based NRF2 gene editing platform, InhaTarget's lipid-nanoparticle formulation technology, and Merxin's inhaler device technology. Initial preclinical studies in cell culture and lung carcinoma mouse models are expected to yield results by mid-2026, with the goal of creating a patient-friendly inhaled therapy that maximizes efficacy and minimizes systemic side effects. Lung cancer is one of the leading causes of cancer-related deaths globally, with over 380,000 new cases of squamous cell carcinoma diagnosed annually and a five-year survival rate below 5%.Business Wire BlogCorrixr Therapeutics Names New CEO to Accelerate Momentum in Lead ProgramCorrixr Therapeutics appointed Hilary Malone as CEO to advance its lead program CXR101 toward first-in-human trials. Malone brings 25+ years of biotech leadership, succeeding Eric Kmiec, who remains as CSCO. The company aims to bring a gene-editing treatment for squamous cell cancers to the clinic.PrecisionmedicineonlineLung Cancer Patients Take a Hit of Inhaled Gene Therapies in TrialsPittsburgh-based Krystal Biotech is advancing an inhaled gene therapy (KB707) for non-small cell lung cancer, with the Phase I/II KYANINE-1 trial showing a 36% objective response rate in heavily pretreated patients; the FDA granted KB707 regenerative medicine advanced therapy (RMAT) designation based on those results, and the company expects to report interim efficacy data and disclose registrational trial plans later this year. Krystal is also studying KB707 in combination with Merck's Keytruda and chemotherapy, while separately CorriXR Therapeutics is developing an inhaled CRISPR gene-editing therapy for squamous cell lung carcinoma in collaboration with Belgium-based InhaTarget Therapeutics and UK-based Merxin.Business Wire BlogCorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid TumorsCorriXR Therapeutics announced publication of peer-reviewed preclinical data in Molecular Therapy Oncology demonstrating that CRISPR-directed gene editing targeting the NRF2 gene resensitized squamous cell lung carcinoma tumors to chemotherapy, with editing just 20–40% of tumor cells sufficient to significantly reduce growth. The study, conducted in collaboration with ChristianaCare's Gene Editing Institute, showed no off-target editing above 0.2% background and validated the approach in both engineered and patient-derived tumor models using a lipid nanoparticle delivery system. The company is now conducting IND-enabling safety and regulatory studies to support an FDA application for human trials and exploring partnerships to accelerate clinical translation.Town Square Delaware LIVECorriXR Therapeutics secures $1M state investment to advance cancer treatmentCorriXR Therapeutics, Inc. has secured a $1 million investment from the State of Delaware to support its development of next-generation cancer treatments targeting solid tumors. This funding is part of the Delaware Accelerator & Seed Capital Program, which aims to help early-stage businesses by providing access to capital.YahooCorriXR Therapeutics Secures $1M Investment from State of DelawareCorriXR Therapeutics announced a $1M investment from the State of Delaware, representing the first investment from the Delaware Accelerator & Seed Capital Program under the federal State Small Business Credit Initiative. The funding will support preclinical studies, manufacturing scale-up, and an investigational new drug submission as the company advances its gene editing therapy targeting solid tumors including head/neck and lung cancers toward a first-in-human clinical trial. Delaware Governor Matt Meyer emphasized the investment aligns with the state's goal to become a Mid-Atlantic innovation hub by supporting early-stage companies commercializing CRISPR-based cancer treatments.Pulse 2.0CorriXR: How This Company Is Using CRISPR/Cas Gene Editing To Develop New MedicinesCorriXR Therapeutics, founded by Eric Kmiec and led by CEO Deborah Moorad, develops a CRISPR/Cas9 gene-editing platform to overcome cancer drug resistance. The company, a spin-out from ChristianaCare, plans its first-in-human clinical trial in the first quarter of 2025.